Britta Randlev
Impact in
- Genetics top 0.5%
- Virus-based gene therapy research
- Biotechnology top 0.5%
- Cancer Research and Treatments
Papers in
- Co-authors
- David H. Kirn (6 shared papers)John Nemunaitis (5 shared papers)Ian Ganly (3 shared papers)Fadlo R. Khuri (3 shared papers)Carla Heise (3 shared papers)James C. Arseneau (3 shared papers)Ann M. Gillenwater (1 shared paper)Waun Ki Hong (1 shared paper)
- Journals
- Gene Therapy (3 papers)Journal of Allergy and Clinical Immunology (2 papers)Molecular Cancer Therapeutics (1 paper)Biologicals (1 paper)Drugs (1 paper)
- Partner nations
- United StatesUnited KingdomNew Zealand
In The Last Decade
Britta Randlev
14 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 74
- Genetics 2.1k
- Biotechnology 572
- Oncology 1.5k
- Molecular Biology 1.6k
- Otorhinolaryngology 70
Countries citing papers authored by Britta Randlev
This map shows the geographic impact of Britta Randlev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Britta Randlev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Britta Randlev more than expected).
Fields of papers citing papers by Britta Randlev
This network shows the impact of papers produced by Britta Randlev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Britta Randlev. The network helps show where Britta Randlev may publish in the future.
Co-authors
The 25 scholars most cited alongside Britta Randlev, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Hit paper breakdown → | 2000 | 858 |
| 2 | 2001 | 369 | |
| 3 | Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. | 2000 | 331 |
| 4 | Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. | 2002 | 251 |
| 5 | 2001 | 228 | |
| 6 | 2001 | 221 | |
| 7 | 2005 | 130 | |
| 8 | 2003 | 70 | |
| 9 | 2005 | 66 | |
| 10 | 1989 | 60 | |
| 11 | 1988 | 7 | |
| 12 | 2010 | 4 | |
| 13 | 1989 | 3 | |
| 14 | 2011 | 2 |
About Britta Randlev
Britta Randlev is a scholar working on Oncology, Genetics, Molecular Biology, Biotechnology and Immunology, having authored 14 papers that have together received 2.6k indexed citations. Recurring topics across this work include Virus-based gene therapy research (9 papers), CAR-T cell therapy research (7 papers), Cancer Research and Treatments (3 papers), Viral Infectious Diseases and Gene Expression in Insects (3 papers), RNA Interference and Gene Delivery (2 papers), Chemokine receptors and signaling (1 paper), Cancer-related Molecular Pathways (1 paper) and Cell Adhesion Molecules Research (1 paper). The work is most often cited by research in Genetics (2.1k citations), Biotechnology (572 citations), Oncology (1.5k citations), Molecular Biology (1.6k citations) and Otorhinolaryngology (70 citations). Britta Randlev has collaborated with scholars based in United States, United Kingdom and New Zealand. Frequent co-authors include David H. Kirn, John Nemunaitis, Ian Ganly, Fadlo R. Khuri, Carla Heise, James C. Arseneau, Ann M. Gillenwater, Waun Ki Hong, R.H. MacDougall and J. Ironside. Their work appears in journals such as Gene Therapy, Journal of Allergy and Clinical Immunology, Molecular Cancer Therapeutics, Biologicals and Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.